Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
186 hedge funds and large institutions have $2.99B invested in Amicus Therapeutics in 2017 Q3 according to their latest regulatory filings, with 58 funds opening new positions, 72 increasing their positions, 38 reducing their positions, and 13 closing their positions.
346% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 13
89% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 38
71% more capital invested
Capital invested by funds: $1.75B → $2.99B (+$1.24B)
32% more funds holding
Funds holding: 141 → 186 (+45)
8% more call options, than puts
Call options by funds: $81.8M | Put options by funds: $75.4M
1.31% less ownership
Funds ownership: 121.86% → 120.55% (-1.3%)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$69.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.1M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$35.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$29.9M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$27.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$28.1M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$24.8M |
| 3 |
Morgan Stanley
New York
|
-$16.6M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$14.2M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$13.6M |
FOLD Hedge Fund Activity: Q3 2017 in Review
186 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q3 2017, worth a combined $2.99B — up 71% from $1.75B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new FOLD positions and 13 closed out — a net gain of 45 holders — while 72 added to existing stakes and 38 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $69.8M. The largest seller was Fidelity Investments, cutting an estimated $28.1M.
- 186 institutional investors held Amicus Therapeutics (FOLD) as of Q3 2017, up from 141 in Q2 2017.
- Funds reported $2.99B of Amicus Therapeutics stock for Q3 2017, up 71% quarter-over-quarter.
- 58 funds opened new Amicus Therapeutics positions in Q3 2017 and 13 closed out, a net change of +45 holders.
- The largest Amicus Therapeutics buyer in Q3 2017 was T. Rowe Price Associates, an estimated $69.8M added.
- The largest Amicus Therapeutics seller in Q3 2017 was Fidelity Investments, an estimated $28.1M sold.
Based on aggregated 13F filings for Q3 2017.